Fig. 2From: A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosisPooled proportions of patients on simvastatin 40Â mg daily that experienced muscle injury or rhabdomyolysis (a), rhabdomyolysis (b) and myalgia (c). Two studies [32, 33] were excluded from the quantitative meta-analyses since they were not indexed in any of the probed databases, had overall poor quality and had a high risk for biasBack to article page